Introduction: Tumour-associated urokinase plasminogen activator (uPA) is a critical marker of invasion and metastasis, and it is recognised as having strong prognostic relevance as well as being a therapeutic target. The specific uPA inhibitor plasminogen activator inhibitor type-2 (PAI-2, SerpinB2) specifically targets cell bound uPA and is internalised. Furthermore, preclinical studies have established the "proof-of-principle" of uPAtargeting by PAI-2-cytotoxin conjugates in human carcinoma models. However, these studies also suggest that PAI-2 is rapidly cleared via the renal system with low total dose reaching the tumour. In this study, a comparative single photon emission computed tomography (SPECT) and biodistribution (BD) analysis of different forms of PAI-2 labelled with the radioisotopes iodine-123 (123I) and technetium-99m (99mTc) was undertaken. Methods: The pharmacokinetic (PK) properties and BD of wild-type, ΔCD-loop and PEGylated ΔCD-loop PAI-2 labelled with the commonly used diagnostic SPECT radioisotopes 99mTc or 123I were compared in mouse models of human prostate carcinoma. Whole body SPECT imaging was also performed. Results: Both wild-type or the shorter but active ΔCD-loop form of PAI-2 123I-labelled indirectly via conjugation to free amine groups (termed 123I-Bn-PAI-2) exhibited low tumour uptake, rapid excretion and similar PK profiles. Preliminary studies with a short branched-chain PEGylated 123I-Bn-PAI-2 ΔCD-loop indicated an increase in blood retention time and tumour uptake. All 123I-Bn-labelled radiotracers were largely excreted through the kidneys. By comparison, both wild-type 123I-PAI-2 (labelled directly via tyrosine residues) and 99mTc-PAI-2 displayed different PK/BD patterns compared to 123IBn-PAI-2, suggesting greater liver based catabolism and thus slower elimination. SPECT imaging mimicked the BD results of all radiotracers. Conclusion: The different labelling methods gave distinct PAI-2 BD and tumour uptake profiles, with radioiodination resulting in the best non-tumour organ clearance profiles. Preliminary analyses with short branched-chain PEGylated 123I-Bn-PAI-2 ΔCD-loop suggest that further investigations with other PEGylation reagents are required to optimise this approach for tumour imaging. These findings impact on the use of PAI-2 for drug delivery and/or diagnostic development. -2 -
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Conclusion:
The different labelling methods gave distinct PAI-2 BD and tumour uptake profiles, with radioiodination resulting in the best non-tumour organ clearance profiles.
Preliminary analyses with short branched-chain PEGylated 123 I-Bn-PAI-2 ∆CD-loop suggest that further investigations with other PEGylation reagents are required to optimise this approach for tumour imaging. These findings impact on t he use of PAI-2 for drug delivery and/or diagnostic development.
Introduction
With an aging population, the worldwide incidence and mortality of cancer is ever increasing and many different methods of diagnosis and therapy have been investigated with varying levels of success [1] . Numerous receptor based targets have been considered for their potential exploitation as targeting entities for use in nuclear medicine. The
Urokinase Plasminogen Activation (uPA) system is one such physiological process that is implicated in tumour invasion and metastasis and has the potential for exploitation in this manner, as over-expression of tumour cell surface uPA has strong prognostic relevance as well as being a therapeutic target [2, 3] . uPA is synthesised and secreted as a zymogen whose activation is markedly accelerated upon binding with high affinity to specific cell surface uPA receptors (uPAR). Active, receptor-bound uPA then efficiently converts any cell surface-bound zymogen plasminogen into the highly active, serine protease plasmin, which promotes tissue degradation and remodelling of the local extracellular environment [4] . The specific uPA inhibitor human plasminogen activator inhibitor type-2 (PAI-2, serpinB2) efficiently inhibits uPAR-bound uPA resulting in proteolytic inhibition and rapid and specific receptor-mediated endocytosis of the uPAR/uPA:PAI-2 complex [5] [6] [7] [8] .
PAI-2 is thus able to efficiently and specifically deliver and concentrate attached cytotoxins within targeted cells [5, 9] . PAI-2 labeled by chelation with the cytotoxic alpha-emitting radionuclide Bismuth-213 ( 213 Bi), targets and significantly reduces tumour growth of human uPA expressing tumours in mouse models [5, [10] [11] [12] . Due to the overexpression of uPA in metastatic cells, PAI-2 could possibly be exploited as a highly specific imaging tool for determining the metastatic potential of tumours.
PAI-2 has high stability in plasma, is non-immunogenic and non-toxic, and has been successfully radiolabelled with the isotopes 213 Bi [10, 11, 13] and 125 I [14] which do not interfere with the protein's uPA inhibitory action. Previous biodistribution (BD) studies in human colorectal tumour-bearing mouse models using human recombinant wild-type PAI-2 radioiodinated directly with 125 I via tyrosine residues, shows rapid clearance from all organs of the animal, with a small amount of uptake in the tumour (1.3% injected dose/g) at early time points [14] . Although this excretion profile is ideal for a diagnostic radiotracer, it is important to increase the tumour uptake of PAI-2 while lowering -5 -radioactivity retention in all normal organs in order to optimise imaging potential and/or drug delivery profiles.
Previous studies have shown that the position, type and structure of the radiolabel can greatly influence the organ and tumour uptake and clearance profiles of proteins and peptides [15, 16] . Furthermore, the ultimate application will dictate the radiolabelling approach to use. S PECT is a commonly used imaging modality. The most commonly used radioisotope for SPECT imaging is 99m
Tc, which has a moderately short half-life of attached directly to proteins tends to be unstable in vivo with the radiolabelled protein being rapidly dehalogenated resulting in thyroid uptake and excretion of free radioiodine [18] . This can be avoided by indirectly labelling the protein by conjugation of a radioiodinated prosthetic group to free amines [18] . A comparative assessment of these different radiolabelling methods on t he PK and BD of PAI-2 has not been previously
undertaken.
An alternative approach to modulating PK and BD profiles of imaging and therapeutic protein-based radiopharmaceutical agents is to modify the protein. This is very well exemplified with targeting antibodies and their fragments [19] with small (6.5 kDa) affibody molecules showing promise for improved imaging of HER-2 positive tumours [20] . Structurally, wild-type PAI-2 (47 kDa) consists of three β-sheets, 9 α-helices and a reactive centre loop (that contains the protease recognition site) [21] . PAI-2 also contains a so-called CD-loop, a sequence of 33 amino acids between the C and D α-helices that may be involved in various intracellular functions [22] , but is not required for uPA inhibition [23] . Removal of the CD-loop to generate the shortened form of PAI-2 (∆CD-loop PAI-2; ~44 KDa) is simpler to express and purify recombinantly, retains full uPA inhibitory characteristics [23] and may potentially exhibit a more favourable PK profile -6 -for imaging as is typically seen when the size of a targeting protein is decreased [24] . The circulation of proteins can also be modified by PEGylation, via conjugation of one or more polyethylene glycol (PEG) units [25] . Addition of PEG groups to targeting moieties has the significant effect of increasing the residence time in the blood stream (due to retardation of renal clearance), hence increasing the bioavailability and clinical potency of the drug [25, 26] . This approach has also been used to increase tumour uptake while decreasing kidney uptake of radiolabeled diabodies for improved SPECT imaging purposes [27] .
Evaluation of modified forms of PAI-2 using different radiolabelling techniques via PK and BD analyses and SPECT imaging, would allow a direct comparison to the known properties of the PK and BD of wild-type 125 I-PAI-2 [14] . Tc radiolabelling methods with modified PAI-2 forms on PK and BD profiles, with a further view to optimising tumour uptake of the radiopharmaceutical for the purpose of tumour imaging and/or radiotherapy.
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Materials and Methods

General
Chemicals and solvents were purchased from Sigma-Aldrich unless otherwise indicated. All reagents and solvents were of the highest commercially available grade and used without further purification. 123 by PAI-2 Pty Ltd (Sydney, Australia) or made in-house as described [23] .
Radiolabelling
Radioiodination of both wild-type and ∆CD-loop PAI-2 was performed using direct and indirect methods. Direct radiolabelling was performed using a modified BoltonHunter method employing Iodogen (10-50 µg) as the oxidant together with the protein (5-50 µg) in PBS (pH 7.4) and Na 123 I (40-800 MBq). Unincorporated 123 I was separated from protein purified using a Zeba desalt spin column as per manufacturer's instructions.
An incorporation yield of 123 I onto PAI-2 of 15-30% was obtained by this method.
Quality control and radiochemical stability were ascertained on a radio-analytical HPLC system consisting of a Waters 616 pum p, a Waters 486 U V-vis (UV= 280 nm) with an inline γ -detector (Ortec) and a B iosep 2000 Phenomenex column (300 x 7.8 mm) or 3000 Phenomenex column (75 x 7.5mm) at 1 ml per min, using a phosphate buffer 100 mM, pH 7.4, NaCl 150 mM mobile phase. The purity and stability of the resultant 123 I-PAI-2 was found to be greater than 95% at room temperature for a minimum of 2 h as assessed by radio-analytical HPLC chromatography. The indirect radiolabelling method was based on a previously described method [28] and involved the conjugation of 123 I-N- 
Radiolabelling of wild-type PAI-2 with 99m
Tc was performed using PAI-2-DTTA [13] using a method modified from Vera et al. [29] . µL of HCl (37%) to 5 mg of SnCl 2 , followed by 25 µL of 0.9% saline). The reaction was incubated at room temperature in the dark for 50 min and then centrifuged at 2000 g for 10 min after which time a one-tenth volume of 10 × sterile PBS (pH 7.4) was added. The mixture was purified using a Zeba desalt spin column as above and the radiotracer analysed by radio-analytical HPLC also as described above. The percent incorporation was > 95%.
All radiolabelling procedures were performed at least three times. Protein stability and inhibitory activity of the radiolabelled PAI-2 species were confirmed by their ability to form complexes with active uPA as detected by SDS-PAGE and autoradiography as previously described [12] [13] [14] (data not shown).
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PEGylation of PAI-2
PEGylation of PAI-2 ∆CD-loop was performed by conjugation of the protein with the branched (methyl-PEO 12 )-PEO 4 -NHS ester as described by the manufacturer and adapted from Hermanson [30] . Briefly, 25 mM (methyl-PEO 12 )-PEO 4 -NHS ester freshly dissolved in anhydrous dimethyl formamide was added to 1 mg/mL PAI-2 in phosphate buffer (pH 8.0) to give > 20-fold molar excess of the PEG reagent to protein. The reaction mixture was incubated for at least 3 h at 37 o C after which the PEGylated protein was purified away from non-reacted PEGylation reagent using a Zeba desalt spin column as above. Protein conjugation and inhibitory activity was confirmed as described above.
In general, >80 % of the protein was PEGylated with 1-4 PEG groups achieved as determined by SDS-PAGE and QTOF-ESI mass spectrometry (Supplementary Figure 2) .
Cell lines and animals
PC-3 human prostate carcinoma cell lines were cultured in RPMI-1640 supplemented with 10% FCS at 37ºC under 5% CO2: 95% atmosphere and cell surface expression of uPAR and uPA was verified by indirect immunofluorescence using dual colour flow cytometry as previously described [5] .
Animal experiments were performed in compliance with the NHMRC Australian 
SPECT Imaging
To further study the pharmacokinetic profiles and hence determine the tumour imaging potential of the above radiotracers, SPECT imaging was performed using a high -10 - Tc and allowing 20,000 counts to be collected. After the uniformity table was collected and applied, the same phantom was rescanned collecting 3000 counts for quality control purposes. QC results indicated the standard deviation in the field of view was < 6% at all times.
Biodistribution (BD)
To Windows, (GraphPad Software, San Diego CA USA). All values were corrected for radioactivity decay and 5 mice were used for each time point.
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Statistics
Statistical significance of different groups was determined using two-way ANOVA or paired two-tailed Students T-test (GraphPad Prism V 5.1; San Diego, CA, USA). P values < 0.05 were considered statistically significant.
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Results
SPECT Imaging Studies
The whole body distribution of wild-type 123 I-PAI-2, 123 I-Bn-PAI-2 and appeared to be higher than for the non-PEGylated radiotracer ( Figure 1D ).
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These observations were confirmed quantitatively as described in the following PK and BD studies.
Blood clearance evaluations
As suggested by SPECT imaging, blood levels of radioactivity in mice injected with 123 I-Bn-PAI-2 or 123 I-Bn-PAI-2 ∆CD-loop rapidly declined between 5 and 60 min ( Figure   2A and B, respectively). This was especially the case for 123 I-Bn-PAI-2 ∆CD-loop, with radioactivity reaching detection limits 3 h after administration ( Figure 2B ). There was no distinction between distribution and elimination phases of the radioactivity as the data wild-type PAI-2 exhibits a biphasic PK profile [14] and was seen by SPECT (refer to Figure 1B ) to reside in the body for longer than the indirectly labelled forms (refer to Figures 1A and D) . However, PEGylated 123 I-Bn-PAI-2 ∆CD-loop also exhibited a biphasic pharmacokinetic profile consisting of an initial decay phase of rapid radioactivity distribution (~7 min) followed by a s low decay phase of radioactivity clearance (~ 111 m in) ( Figure 2C ). Compared to the non-PEGylated species there was increased blood retention of radioactivity by 3 h after administration, which was also somewhat reflected in the blood distribution seen in the SPECT images (refer to Figure   1E ).
The 99m
Tc-PAI-2 (wild-type) data best fits a one-phase decay model. Significant amounts of radioactivity remained in the blood 24 h a fter injection as reflected by a longer T 1/2 of 90 min ( Figure 2D ). This also compared well to the SPECT images (refer to Figure 1C ) suggestive of a longer residence time of Tc-PAI-2 in mice compared to any of the radioiodinated protein forms.
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Biodistribution
The BD patterns of the differently radiolabelled PAI-2 forms in mice bearing prostate tumours were determined over 24 h. Within the first 30 min after injection of 123 I-Bn-PAI-2 ∆CD loop, kidneys and livers exhibited the greatest uptake of radioactivity which quickly declined thereafter (Table 1) . This pattern was reflected in the other organs analysed with any substantial uptake (> 2% ID/g), except for thyroid and tumour (discussed further below). Whilst a similar metabolic pattern for most organs was seen after administration of 123 I-Bn-PAI-2, kidney uptake and elimination of radioactivity levels was slower than for 123 I-Bn-PAI-2 ∆CD-loop in the first hour (Table 1) Tc-PAI-2 differed from all of the radioiodinated forms where substantial uptake of radioactivity was evident within the first 5 min after injection into all major organs including heart and lungs, with very slow to no clearance seen after 6 h (Table 1) . Indeed, after 24 h many organs still retained > 4% ID/g. Tc-PAI-2 showed higher thyroid uptake overall, these values were still relatively low (minimal thyroid uptake seen in SPECT images shown in Figure 1 ).
The pattern of tumour uptake of radioactivity was somewhat modulated by the different radiolabelling methods and modifications to PAI-2 protein (Figure 3 ). For the wild-type protein, radioiodination versus radiometal labelling resulted in significantly different radioactivity uptake levels at all time points (p <0.01) ( Figure 3A) . A maximum uptake of 0.85 ± 0.24 % ID/g occurred at 60 min after 123 I-Bn-PAI-2 injection with a steady decline in radioactivity levels thereafter. In contrast, radioactivity levels peaked at -15 - Figure 3B ). For both radiotracers, tumour radioactivity levels declined to < 0.2 % ID/g by 3 h after injection ( Figure 3B ). PEGylated 123 I-Bn-PAI-2 ∆CD-loop resulted in a maximum uptake of radioactivity at 5 min post injection at a l evel (1.6 ± 0.22% ID/g) that was significantly greater than that attributable to non-PEGylated 123 I-Bn-PAI-2 ∆CD-loop at this time point (0.71 ± 0.16% ID/g) (p < 0.001) ( Figure 3C ). Thereafter, the levels of radioactivity in tumours after injection of PEGylated 123 I-Bn-PAI-2 ∆CD-loop compared to non-PEGylated 123 I-Bn-PAI-2 ∆CD-loop were not significantly different from each other ( Figure 3C ).
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Discussion
The aim of these studies were to perform a comparative SPECT and BD analysis of radioiodinated versus 99m
Tc-labelled wild-type PAI-2, and radioiodinated wild-type versus the shortened PAI-2 ∆CD-loop form in order to assess organ distribution and clearance patterns for potential future development as imaging agents for cancer and for therapeutic radioisotope delivery. Further to this latter application, PEGylation of PAI-2 ∆CD-loop was explored as part of an initial investigation to assess the potential to increase tumour uptake for radiotherapy. As expected, the different labelling methods modulated the PK and BD properties of PAI-2 to varying degrees. While no significant benefit in terms of tumour uptake was obtained through use of the shortened version of the protein, PAI-2 ∆CD-loop retains full uPA inhibitory activity and is more easily expressed and purified compared to wild-type PAI-2 [23] , thus lending itself to a simpler manufacturing process. Moreover PAI-2 ∆CD-loop can be modified by PEGylation whilst retaining its activity and prolonging blood retention and tumour uptake of radiotracer.
Compared to directly radioiodinated PAI-2 where radioactivity associated with the thyroid is significant (refer to Figure 1B ) due to either dehalogenation and/or metabolism of the radiotracer (intact radioiodinated species were found in plasma 2 h a fter administration [14] ), the very low 123 I levels associated with the thyroid after administration of indirectly radioiodinated wild-type or ∆CD-loop PAI-2 suggest that the radiotracers were not metabolised but rather were cleared via the renal system intact.
Whether this is indeed the case would need to be verified by analyses of plasma and urine samples however, the single phase blood clearance properties and minimal uptake by discrete organs other than the kidneys lends favour to this hypothesis. Studies have shown that 111 In-protein complexes achieved using the chelator DOTA may be more stable in vivo and result in enhanced tissue accumulation of radioactivity [31] . Indeed this appeared to be the case when comparing organ BD of wild-type While tumour uptake of radioactivity was also increased and cleared more slowly by -17 -
Tc-PAI-2 compared to the radioiodinated forms, this is potentially at the detriment of also accumulating radioactivity in non-target organs.
Over the first 3 h i n which radioactivity was detectable in tumours by BD studies, tumour uptake using all forms of radiolabelled PAI-2 was many times less than that in the blood on a per gram basis, resulting in no t umour imaging capability. The contrast required to detect tumour masses via imaging compared to normal tissue requires in the least that the amount of radiotracer circulating in blood to be lower than that in the tumour on a percent per gram of tissue basis. However the amount of radiotracer distributed to other non-tumour tissues other than the liver and kidneys, were exceptionally low, particularly after 1 h pos t radiotracer injection, suggesting potential for further optimisation as a tumour imaging agent.
Directly radioidinated wild-type 125 I-PAI-2 levels peaked in tumours at 30 -60 min at 1 -2 %ID/g [14] . That protein reached the tumours was verified by immunoprecipitation of PAI-2 in previous studies [14] . A similar temporal profile was observed using either These promising preliminary PEGylation studies suggest that further refinement in this area may be obtained to produce better PK properties of the radiotracer for use in radiotherapy. As the PEGylated PAI-2 ∆CD-loop form used in this study was less than 70 kDa (Supplementary Figure 2) , it is still considered small enough to be eliminated via the renal system [25] . A ttachment of longer chain length PEG groups will increase the molecular weight of the PEGylated protein complex [25] , and hypothetically lead to longer blood retention thus greater opportunity for PAI-2 to interact with cell surface -18 -associated uPA. Larger PEGylated PAI-2 species would find further application in radiotherapy as the modified protein may increase the payload of conjugated therapeutic radiometals delivered to the tumour whilst decreasing kidney uptake. Success has already been derived using 213
Bi-PAI-2 in targeted alpha particle radiotherapy towards metastatic cancer [11, 12] . We are currently optimizing methods for site-directed conjugation of larger PEG groups using different PEGylation techniques, chain lengths and molecular weights (up to 30 kD a), in order to identify the most advantageous changes in biopharmacokinetic properties to PAI-2.
The human prostate carcinoma mouse model was selected on the basis that the PC-3 cells were, before implantation, shown to express uPA and the model has been used successfully previously for tumour efficacy studies investigating 
